C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study (Q46788361)

25 December 2017

http://europepmc.org/abstract/MED/25576381

title

C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study (English)

1 reference

25 December 2017

http://europepmc.org/abstract/MED/25576381

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Lan Yang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Li-Yun Zheng

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ye Tian

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Zhi-Qing Zhang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Xu-Fen Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Xiao-Ying Zhang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Cong Cao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

6 January 2015

1 reference

25 December 2017

http://europepmc.org/abstract/MED/25576381

published in

Experimental Cell Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

332

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

47-59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

The global breast cancer burden: variations in epidemiology and survival.

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Reducing the global breast cancer burden: the importance of patterns of care research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Single agent versus combination chemotherapy for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Single agent versus combination chemotherapy for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Ceramide: an intracellular signal for apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Signal transduction of stress via ceramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Killing tumours by ceramide-induced apoptosis: a critique of available drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Trojan-horse nanotube on-command intracellular drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Identification of TGF-β-activated kinase 1 as a possible novel target for renal cell carcinoma intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Impairment of TrkB-PSD-95 signaling in Angelman syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Ultra-violet B (UVB)-induced skin cell death occurs through a cyclophilin D intrinsic signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Calcium, mitochondria and reperfusion injury: a pore way to die.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

The permeability transition pore complex: another view.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

DeltaPsi(m)-Dependent and -independent production of reactive oxygen species by rat brain mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Mitochondrial permeability transition and cell death: the role of cyclophilin d

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Activation of AMPK protects against hydrogen peroxide-induced osteoblast apoptosis through autophagy induction and NADPH maintenance: new implications for osteonecrosis treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

More about: prognostic importance of low c-erbB2 expression in breast tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.12.017

10.1016/J.YEXCR.2014.12.017

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25576381%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference